Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

bectumomab

Known as: IMMU-LL2-Fab, MAb LL2 (EPB2), monoclonal antibody IMMU-LL2-Fab 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Diffuse Large B-Cell Lymphomas (DLBCLs) are the most common histologic subtype within non-Hodgkin’s lymphomas (NHLs), accounting… Expand
2008
2008
On January 1, 2000, Medicare extended the coverage of immunosuppression medications from 3 years to life for elderly and disabled… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
2004
2004
Mangeat B, Turelli P, Caron G, et al. Nature. 2003;424:99–102 Innate intracellular antiretroviral defense mechanisms have been… Expand
2004
2004
Un examen des concepts utilises par l'immunologie conduit a s'interroger sur l'origine et la legitimite des notions de soi et de… Expand
2002
2002
UNLABELLED The efficacy of a Tc99m-labeled anti-lymphoma antibody fragment, bectumomab [LymphoScan], was retrospectively examined… Expand
1996
1996
Dr. Hatem Mansy, Senior Consultant Nephrologist, North West Armed Forces, Hospitals Program, Tabuk (Saudi Arabia) Dear Sir… Expand
Review
1996
Review
1996
Commentary Short term immunosuppressive therapy and long term immunoregulation: promises and problems Immune mechanisms are… Expand
1993
1993
In the last 20 years an unusually high incidence of acute promy-elocytic leukemia (APL) has been observed at the Monza pediatric… Expand
  • table 1
  • table 2
Highly Cited
1988
Highly Cited
1988
We have demonstrated that one Fc receptor for IgG (FcR) (CD16) on cultured human monocytes appears to be a developmentally… Expand
  • figure 2
  • figure 3
  • table I
  • table II
  • figure 5
Highly Cited
1975
Highly Cited
1975
constant and variable sequences which may occur either at the level of DNA or RNA. It is now generally accepted, that both B and… Expand